Skip to content

Study for optimizing the calculation of insulin dose in insulin tolerance test (ITT)

Study for optimizing the calculation of insulin dose in insulin tolerance test (ITT)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023871
Enrollment
Unknown
Registered
2019-06-15
Start date
2019-06-19
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypopituitarism

Interventions

Usual treatment group:Insulin dosage in ITT was calculated at 0.15U/kg body weight
Experimental group:Insulin dosage in ITT will be calculated at ? U/kg body weight (? = - 0.034+ 0.000176×AUCINS+ 0.01×BMI)

Sponsors

Ruijin Hospital North Campus, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 50 male or female; 2. Diagnosed as congenital GHD (or congenital hypopituitarism) in childhood or in line with the clinical symptoms and signs related to congenital GHD; 3. Evidence of clinical symptoms and signs related to GHD in patients with previous hypothalamic-pituitary diseases (secretory, craniocerebral structure or genetic abnormality); 4. Patients who have received craniocerebral tumor treatment (including surgery and radiotherapy); 5. Patients who participated in the experiment after the operation of sellar region or pituitary tumor were all more than 6 months after the operation; 6. Voluntarily participate and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients with a history of malignant tumor; 2) Patients with diabetes or have used hypoglycemic drugs; 3) Patients with intracranial hypertension; 4) Patients with severe liver and kidney dysfunction; 5) Patients with a history of heart disease, including ischemic heart disease, fatal arrhythmia, and cardiac dysfunction; 6) Patients with a history of epilepsy; 7) Pregnant and lactating women; 8) Patients with severe hypertension, blood pressure > 180/110 mmHg (1 mmHg = 0.133 kPa); 9) Patients undergoing antidepressant therapy, immunosuppressive therapy, chemotherapy and radiotherapy (except for pituitary diseases); 10) Psychopaths.

Design outcomes

Primary

MeasureTime frame
The ratio of developed hypoglycemia with one dose of insulin in ITT;

Secondary

MeasureTime frame
Lowest blood glucose in ITT;The ratio of severe hypoglycemia in ITT;

Countries

China

Contacts

Public ContactZhang Yuwen

Ruijin Hospital North Campus, Shanghai Jiaotong University School of Medicine

bfzyw@163.com+86 13916109997

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026